title: Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
authors.forename: Jens
authors.initials: J
authors.lastname: Lundgren
authors.forename: Abdel
authors.initials: A
authors.lastname: Babiker
authors.forename: Fred
authors.initials: F
authors.lastname: Gordin
authors.forename: Sean
authors.initials: S
authors.lastname: Emery
authors.forename: Gerd
authors.initials: G
authors.lastname: Fätkenheuer
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Molina
authors.forename: Robin
authors.initials: R
authors.lastname: Wood
authors.forename: James D
authors.initials: JD
authors.lastname: Neaton
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D008297:Male; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D044966:Anti-Retroviral Agents
keywords: CD4-guided ART; HIV; START trial; antiretroviral therapy; when to start